By standardizing the methodologies, future research studies can enhance data comparability and clarify the role of vascular factors like CD34+ cells as potential diagnostic or prognostic biomarkers in AD patients, paving the path for novel therapeutic strategies. This evidence concerns the gene CD34 and Alzheimer disease.